A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

被引:44
作者
Bekker, PJ
Holloway, DL
Rasmussen, AS
Murphy, R
Martin, SW
Leese, PT
Holmes, GB
Dunstan, CR
DePaoli, AM
机构
[1] Amgen Inc, Newbury Pk, CA 91320 USA
[2] Quintiles, Lenexa, KS USA
[3] SFBC Int Inc, Miami, FL USA
[4] ANZAC Res Inst, Concord, NSW, Australia
关键词
RANKL; osteoprotegerin; osteoporosis; bone resorption; AMG; 162;
D O I
10.1359/jbmr.2005.20.12.2274
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The safety and bone antiresorptive effect of a single subcutaneous dose of AMG 162, a human monoclonal antibody to RANKL, was investigated in 49 postmenopausal women. AMG 162 is a potent antiresorptive agent for diseases such as osteoporosis.
引用
收藏
页码:2274 / 2282
页数:9
相关论文
共 50 条
  • [41] RANK ligand and osteoprotegerin in myeloma bone disease
    Sezer, O
    Heider, U
    Zavrski, I
    Kühne, CA
    Hofbauer, LC
    [J]. BLOOD, 2003, 101 (06) : 2094 - 2098
  • [42] Osteoprotegerin: A novel secreted protein involved in the regulation of bone density
    Simonet, WS
    Lacey, DL
    Dunstan, CR
    Kelley, M
    Chang, MS
    Luthy, R
    Nguyen, HQ
    Wooden, S
    Bennett, L
    Boone, T
    Shimamoto, G
    DeRose, M
    Elliott, R
    Colombero, A
    Tan, HL
    Trail, G
    Sullivan, J
    Davy, E
    Bucay, N
    RenshawGegg, L
    Hughes, TM
    Hill, D
    Pattison, W
    Campbell, P
    Sander, S
    Van, G
    Tarpley, J
    Derby, P
    Lee, R
    Boyle, WJ
    [J]. CELL, 1997, 89 (02) : 309 - 319
  • [43] Mutation screening of the TNFRSF11A gene encoding receptor activator of NFκB (RANK) in familial and sporadic Paget's disease of bone and osteosarcoma
    Sparks, AB
    Peterson, SN
    Bell, C
    Loftus, BJ
    Hocking, L
    Cahill, DP
    Frassica, FJ
    Streeten, EA
    Levine, MA
    Fraser, CM
    Adams, MD
    Broder, S
    Venter, JC
    Kinzler, KW
    Vogelstein, B
    Ralston, SH
    [J]. CALCIFIED TISSUE INTERNATIONAL, 2001, 68 (03) : 151 - 155
  • [44] Breast cancer cells interact with osteoblasts to support osteoclast formation
    Thomas, RJ
    Guise, TA
    Yin, JJ
    Elliott, J
    Horwood, NJ
    Martin, TJ
    Gillespie, MT
    [J]. ENDOCRINOLOGY, 1999, 140 (10) : 4451 - 4458
  • [45] Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women
    Tonino, RP
    Meunier, PJ
    Emkey, R
    Rodriguez-Portales, JA
    Menkes, CJ
    Wasnich, RD
    Bone, HG
    Santora, AC
    Wu, M
    Desai, R
    Ross, PD
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (09) : 3109 - 3115
  • [46] Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis
    Tsuda, E
    Goto, M
    Mochizuki, S
    Yano, K
    Kobayashi, F
    Morinaga, T
    Higashio, K
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 234 (01) : 137 - 142
  • [47] Osteoprotegerin deficiency and juvenile Paget's disease
    Whyte, MP
    Obrecht, SE
    Finnegan, PM
    Jones, JL
    Podgornik, MN
    McAlister, WH
    Mumm, S
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (03) : 175 - 184
  • [48] Identification and characterization of a new member of the TNF family that induces apoptosis
    Wiley, SR
    Schooley, K
    Smolak, PJ
    Din, WS
    Huang, CP
    Nicholl, JK
    Sutherland, GR
    Smith, TD
    Rauch, C
    Smith, CA
    Goodwin, RG
    [J]. IMMUNITY, 1995, 3 (06) : 673 - 682
  • [49] Osteoclast differentiation factor is a ligand for osteoprotegerin osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
    Yasuda, H
    Shima, N
    Nakagawa, N
    Yamaguchi, K
    Kinosaki, M
    Mochizuki, S
    Tomoyasu, A
    Yano, K
    Goto, M
    Murakami, A
    Tsuda, E
    Morinaga, T
    Higashio, K
    Udagawa, N
    Takahashi, N
    Suda, T
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (07) : 3597 - 3602
  • [50] Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone
    Zhang, J
    Dai, JL
    Qi, YH
    Lin, DL
    Smith, P
    Strayhorn, C
    Mizokami, A
    Fu, Z
    Westman, J
    Keller, ET
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2001, 107 (10) : 1235 - 1244